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Natural killer (NK) cells are a key constituent of the innate immune system, protecting
against bacteria, virally infected cells, and cancer. Recognition and protective function
against such cells are dictated by activating and inhibitory receptors on the surface of the
NK cell, which bind to specific ligands on the surface of target cells. Among the activating
receptors is a small class of specialized receptors termed the natural cytotoxicity recep-
tors (NCRs) comprised of NKp30, NKp46, and NKp44. The NCRs are key receptors in the
recognition and termination of virally infected and tumor cells. Since their discovery over
10 years ago, ligands corresponding to the NCRs have largely remained elusive. Recent
identification of the cellular ligands for NKp44 and NKp30 as exosomal proliferating cell
nuclear antigen (PCNA) and HLA-B-associated transcript 3 (BAT3), respectively, implicate
that NCRs may function as receptors for damage-associated molecular pattern (DAMP)
molecules. In this review, we focus on NKp44, which surprisingly recognizes two distinct
ligands resulting in either activation or inhibition of NK cell effector responses in response
to tumor cells. The inhibitory function of NKp44 requires further study as it may play a
pivotal role in placentation in addition to being exploited by tumors as a mechanism to
escape NK cell killing. Finally, we suggest that the NCRs are a class of pattern recognition
receptors, which recognize signals of genomic instability and cellular stress via interaction
with the c-terminus of DAMP molecules localized to the surface of target cells by various
co-ligands.
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INTRODUCTION
Natural killer (NK) cells are a fundamental component of the
innate immune system, capable of recognizing and destroying
tumor cells as well as cells infected by viruses or bacteria (1,
2). NK cells also secrete cytokines such as interferon-γ (IFN-γ)
and thus regulate the function of other immune cells. Further-
more, NK cells play an important role in adaptive immunity by
modulating dendritic cell function and recent findings demon-
strate that NK cells have memory (3, 4). The ability of NK cells
to kill target cells and secrete cytokines is regulated by a delicate
balance of activating and inhibitory signals received through dis-
tinct classes of receptors found on their cell surface. The balance
of signals delivered by those receptors governs NK cell activa-
tion, proliferation, and effector functions (5–8). Traditionally,
inhibitory killer cell immunoglobulin like receptors (KIRs) and
killer cell lectin-like receptors (KLRs) bind cell surface human
leukocyte antigen class I (HLA I) molecules expressed by healthy
human cells and signal through immunoreceptor tyrosine-based
inhibitory motifs (ITIMS) (9–11). When HLA I interacts with
inhibitory receptors, dominant inhibitory signaling transmitted
by ITIMS prevents activation and cytotoxic action by the NK cell
against normal, healthy cells of the body. NK cells may also be
inhibited by cytokines released by regulatory cells of the immune
system,such as regulatory T cells and myeloid suppressor cells (12).
Activating receptors, including the natural cytotoxicity recep-
tors (NCRs), NKG2D, and 2B4, bind ligands induced by cellular
stress, infection, or tumor transformation (13–16). Activating
signals are transmitted through immunoreceptor tyrosine-based
activating motifs (ITAMs) located in the cytoplasmic tail of the
receptor or through ITAMs in adaptor molecules, which associate
with activating receptors at the cell surface (8, 17). Therefore, when
a target cell lacks or under expresses HLA I and/or over expresses
activating ligands, NK cells eliminate that target by releasing pre-
formed cytotoxic granzymes and perforin stored as granules or
activate apoptosis pathways in the target cell (8, 18).
NATURAL CYTOTOXICITY RECEPTORS
Among the activating receptors is a specialized group of recep-
tors called the NCRs, which play a key role in recognition and
killing of tumor and virally infected cells. Comprising the NCRs
are the NKp44, NKp30, and NKp46 receptors. Binding of one
or more of these receptors with a specific ligand induces strong
NK cell activation and cytotoxicity (19). For optimal recognition
and elimination of target cells, the NCRs work best as a team
when identifying potential targets (20). This is evident through
increased cytotoxicity when multiple NCRs are triggered versus an
individual receptor, suggesting simultaneous NCR ligand expres-
sion on target cells (20, 21). Several studies have identified and
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characterized NCR ligands. NKp46 recognition of a ligand on
tumor cells has been shown to play a role in prevention of tumor
metastasis (22, 23). NKp30 is known to bind B7-H6, a mem-
ber of the B7 family expressed exclusively on tumor cells (24).
While many NCR ligands remain unidentified, they are believed
not to be expressed by normal cells but induced by cellular stress
or pathological conditions (14).
NKp44
NKp44 is unique and significant for several reasons. First, expres-
sion of the receptor is restricted to activated NK cells capable of
initiating an immediate cytotoxic response (25). Second, NKp44
activating function is implicated in HIV-related T cell decline as
expression of an activating ligand for NKp44 is induced in unin-
fected CD4 T cells by the gp41 envelope protein of HIV (26).
Earlier studies have shown recognition of viral hemagglutinins of
influenza virus by NKp44 enhanced killing of infected cells (27).
Finally, NKp44 expression is responsible for a dramatic increase
in killing of many tumor cell lines and cross linking the recep-
tor results in the release of cytotoxic granules, IFN-γ, and TNF-α
(25, 28–30). While only found on activated NK cells in circu-
lation, NKp44 is constitutively expressed by a specialized subset
of NK cells in the decidua, implicating a role for NKp44 during
placentation (25, 31, 32). NKp44 is also expressed on a subset
of interferon-producing cells located in human tonsils and ILC3
cells in mucosal-associated lymphoid tissues and human decidua
(33–37). Recently, it has been shown that NKp44 is indeed func-
tional in ILC3 and its engagement results in TNF but not in IL-22
production (38).
Crystallographic structure of NKp44 demonstrates a surface
groove made by two facing β hairpin loops extending from the
Ig fold core stabilized by a disulfide bridge between Cystine 37
and Cystine 45 (39). The Ig domain contains an arrangement of
positively charged residues at the groove surface, suggesting that
NKp44 ligands are anionic (39). Also, the groove appears wide
enough to host a sialic acid or an elongated branched ligand.
Interestingly, the cytoplasmic tail of NKp44 contains a tyrosine
sequence resembling an ITIM (25, 40). Contrary to initial reports,
this motif is functional and inhibits the release of cytotoxic agents
and IFN-γ (25, 30, 40). NKp44 surface expression is dependent on
its association with the ITAM containing DAP 12 accessory pro-
tein linked to NKp44 through Lysine 183 in the transmembrane
domain (25). Upon recognition of activating ligands, signaling
transduced through the ITAMs in Dap 12 result in release of
cytotoxic agents, tumor necrosis factor-α, and IFN-γ (29, 40).
While NK cells utilize NKp44 to recognize and kill targets,
tumors may also exploit NKp44 to escape NK cell recognition.
By engaging NKp44, as well as the other NCRs, tumors can induce
NK cell death via up regulation of Fas Ligand in the NK cell, induc-
ing Fas-mediated apoptosis (41). Tumors may also downregulate
NKp44 surface expression by shedding soluble MHC Class I chain-
related molecules or by releasing indoleamine 2,3-dioxygenase and
prostaglandin E2 (42, 43). The latter two molecules are released by
mesenchymal stem cells as well, inhibiting NKp44 expression in
the tumor microenvironment (44). Additionally, tumors can reg-
ulate NKp44 ligand expression to escape NK cell killing, as is the
case with acute myeloid leukemia (45). Finally, tumor cells may
induce expression of exosomal proliferating cell nuclear antigen
(PCNA) when physically contacted by NKp44 expressing NK cells
to inhibit NK cell effector function (30).
In addition to its role in immunity, NKp44 also has roles during
pregnancy. Decidual NK cells (dNK) make up 50–90% of lympho-
cytes in the uterine mucosa during pregnancy and constitutively
express NKp44 (36, 46, 47). Trophoblast cells and maternal stro-
mal cells of the decidua both express unidentified NKp44 ligands
(46). This ligand may be PCNA as the protein is over expressed in
trophoblast cells during the first trimester (48). As an inhibitory
ligand for NKp44, extracellular PCNA expression on trophoblast
cells would help explain the diminished ability of dNK cells to lyse
trophoblasts despite low levels of classical HLA I expression (47).
NKp44 TUMOR LIGANDS
NKp44 is implicated in recognition and killing of numerous types
of cancer: neuralblastoma, choriocarcinoma, pancreatic, breast,
lung adenocarcionma, colon, cervix, hepatocellular carcinoma,
Burkitt lymphoma, diffuse B cell lymphoma, prostate (15, 21, 28).
While most of these ligands have not been identified, they appear
to be cell cycle regulated, with down regulation of expression dur-
ing mitosis (28). Recognition of tumor cells is partially mediated
through charged-based binding of NKp44 with heparan sulfate
proteoglycans (HSPGs) on the surface of tumor cells (49–51). Of
note, recognition of HSPG only evokes IFN-γ release by NK cells,
not cellular cytotoxicity (49). Thus, HSPGs are believed to only
be a co-ligand for NKp44 as well as the other NCRs, potentially
facilitating binding with other cellular ligands.
Proliferating cell nuclear antigen is the inhibitory tumor lig-
and for NKp44 (15, 30). PCNA is a nuclear protein found in all
replicating cells, which encircles DNA and increases processivity
of DNA replication, but is also involved in DNA repair and cell
cycle control (52). NKp44 recognizes PCNA expressed on exo-
somes shuttled to the surface of tumors cells when in contact with
NK cells (15, 30). Recognition of cell surface PCNA colocalizing
with HLA I on the cell surface inhibits NK cell cytotoxicity and
IFN-γ release (15).
A truncated isoform of mixed-lineage leukemia-5 (MLL5) is an
activating cellular ligand for NKp44 (53). This MLL5 isoform con-
tains a specific exon encoding a C-terminus, which interacts with
NKp44 (53). Typically located only in the nucleus, MLL5 is a lysine
methyltransferase implicated in hematopoietic differentiation and
control of the cell cycle (53). Contrary to normal MLL5, the iso-
form recognized by NKp44 is not found in the nucleus but in the
cytoplasm and endoplasmic reticulum, destined to be expressed
at the cell surface (53). While MLL5 is expressed in normal tissue,
the isoform recognized by NKp44 is only present on tumor and
transformed cells (53).
NCR CO-LIGANDS
Heparan sulfate proteoglycans have been identified as co-ligands
involved in the recognition of tumor cells by the NCRs (49, 50,
54). HSPGs are complex glycoproteins found at the cell surface of
mammalian cells or in the extracellular matrix (55, 56). Heparan
sulfate is characterized by chains of disaccharide units of N-
acetyl-d-glucosamine linked to d-glucuronic acid (55, 57). Inter-
estingly, each NCR recognizes distinct forms of heparan sulfate
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epitopes on HSPGs, specifically highly sulfated microdomains
on disaccharide units (58). 2-O-sulfation of iduronic acid and
N -acetylation of glucosamine on HSPGs are important for inter-
action with NKp44 (50). NKp30 and NKp46 recognize HSPGs
with 2-O-sulfation of iduronic acid and either 6-O-sulfation or 6-
N-sulfation of glucosamine (50). Interactions between the NCRs
and HSPGs are charge based as each NCR contains basic amino
acid residues in their binding cleft and HSPGs are heavily charged
molecules.
In addition to HSPGs, HLA I may also serve as a co-ligand for
the NCRs. We have shown that HLA I and the NKp44 inhibitory
ligand, PCNA, associate on the cell surface (15). In our search to
identify a ligand for NKp44, several key pieces of evidence sug-
gested that HLA I plays a role in ligand formation. First, HLA I
has been demonstrated to coimmunoprecipitate with anti-NKp44
antibodies; reciprocally, NKp44 coimmunoprecipitates with anti-
β-2-microglobulin antibodies (59). Additionally, the Nef protein
of HIV prevents surface expression of NKp44 ligand isoform of
MLL5 on CD4-infected T cells, which is also consistent with the
ability of Nef to retain HLA I intracellularly (60, 61). Finally, the
NKp30 ligand, Bat3, colocalizes with HLA I on the extracellular
membrane of tumor cells, activating NK cell effector functions
(62, 63). Interestingly, all 50 alleles of HLA Class A, B, and C mol-
ecules harbor an Asparagine at position 86, close to the residues
on the α1 helix, which determine interactions with human NK
receptors (64). This site allows for attachment of N-linked gly-
can structures, which could enable binding of other proteins (64).
Electron density mapping of the HLA I glycan structure suggests
that it is flexible and could serve as a ligand for other receptors
or block access to HLA I molecules. Additionally, HLA-A and -
B are almost exclusively disialylated, resulting in these molecules
having a negative charge, a characteristic of NKp44 ligands (64).
This negative charge combined with a protruding oligosaccharide
could potentially facilitate interactions with NKp44.
As co-ligands, HSPGs and HLA I most likely facilitate binding
of other proteins, which together form a complex ligand rec-
ognized by the NCRs. The most prevalent interaction between
HSPGs and other proteins is charged based via clusters of posi-
tively charged amino acids on proteins forming ionic bonds with
negatively charged sulfate and carboxyl groups on HSPGs (57).
HSPGs may offer two mechanisms facilitating NCR ligand recog-
nition. First, HSPGs may bind soluble proteins, which as a whole
serve as ligands for the NCRs. Second, HSPGs could bind a soluble
protein and an NCR separately, and then act as scaffolding to bring
the NCRs into contact with a soluble protein. In the same manner,
the protruding oligosaccharide of HLA I, or other regions, may
enable assimilation of small proteins or DAMPs.
DAMPs AND THE C TERMINUS
Immune responses are initiated by pattern recognition recep-
tors, which recognize microbial-derived products called pathogen-
associated molecular pattern molecules (65). In a similar manner,
pattern recognition receptors also recognize molecules released
by dying or damaged cells, termed damage-associated molecu-
lar pattern (DAMP) molecules or alarmins (66, 67). Recogni-
tion of DAMPs contributes to the induction of inflammation,
even in the absence of pathogens (68). Normally residing in the
nucleus, cytoplasm, or exosomes, DAMPs lack secretion signals
but can be actively secreted by non-classical pathways or passively
released by necrotic cells (67). DAMPs thus serve as endogenous
danger signals when improperly released from damaged cells as
well as tumors and activate innate immune cells (67). DAMPs
are most often released after trauma, ischemia, or other tissue
damage and initiate early inflammatory responses (67). By recruit-
ing immune cells and promoting the release of proinflammatory
mediators, DAMPs activate immune responses and initiate path-
ways leading to tissue repair and regeneration (67, 69). Heat shock
proteins, high-mobility group box 1 (HMGB1), S100 proteins,
hyaluronan, and heparan sulfate represent a few DAMPs known
to date (68).
Like PAMPs, DAMPs are also recognized by pattern recognition
receptors. In addition to binding PAMPs, the Toll-like receptors
(TLRs) also recognize HMGB1 and a member of the S100 fam-
ily (67). These two DAMPs are also recognized by the receptor
for advanced glycation end products (RAGE) (67). Like the TLRs,
RAGE is expressed on numerous immune cells and induces NF-
κB-mediated production of cytokines (67). Interestingly, DAMP
molecules such as high-mobility group protein B1 and S100A8/9
have the ability to bind heparin sulfate and HSPGs, which are
known to be co-ligands involved in NCR-dependent recognition
of tumor cells resulting in secretion of IFN-γ but not cytotoxicity
(49, 50, 67).
We postulate that DAMPs may serve as the missing link in NCR-
mediated recognition of tumor cells. The association of DAMPs
with HSPGs, HLA I, or other potential co-ligands may form larger
complex ligands for the members of the NCR family (Figure 1).
Human leukocyte antigen-B-associated transcript 3 (Bat3), also
known as BAG-6, could be considered a DAMP due to its release
from tumor cells (62). Bat3 is typically located in the nucleus where
it plays an essential role in controlling the acetylation of p53 in
response to cellular DNA damage (62). However, upon non-lethal
heat shock, nuclear Bat3 relocates to the cell membrane of tumors
where it serves as a ligand for NKp30 (62, 63). Interestingly, this
study found Bat3 colocalizes with HLA I, suggesting opposition to
previous reports that NCRs do not associate with HLA I molecules
(29, 63, 70).
Like Bat3, PCNA and MLL5 are located in the nucleus and cyto-
plasm. Additionally, all three molecules are intricately involved in
processes regulating the cell cycle and/or DNA repair mechanisms.
Thus, their presence on the cell surface may indicate intracellular
stress related to DNA damage or improper cell cycle control, qual-
ifying these molecules as DAMPs. This suggests that the NCRs
may be pattern recognition receptors, which recognize DAMPs
sequestered to the cell surface. Taken into context with other stud-
ies, the NCRs potentially have the ability to interact with HLA I,
HSPGs, or other cell surface molecules as co-ligands in conjunc-
tion with soluble proteins, such as Bat3, PCNA, MLL5, or other
DAMPs on the cell surface of tumors (62). Therefore, the NCRs
may recognize DAMPs on the cell surface in association with a
docking protein. Furthermore, the NCRs may be directly recog-
nizing the C-terminal ends of DAMPs. NKp30 was recently shown
to recognize the C terminus of Bat3 (71). In a similar manner,
NKp44 also recognizes the C terminus of the MLL5 ligand (53).
The molecular details of interaction between NKp44 and PCNA
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FIGURE 1 | Mechanism by which tumor cells may inhibit natural cytotoxicity through NCR recognition by DAMPs. The association of DAMPs with
HSPGs, HLA I, or other potential co-ligands may form larger complex ligands for the members of the NCR family.
have yet to be determined, but the above precedents suggest that
interaction may occur at the C terminus of PCNA.
Natural cytotoxicity receptors ligands consisting of a DAMP
and a co-ligand may add complexity in understanding how the
NCRs regulate NK cell effector function. The NCRs were origi-
nally believed to be strictly activating NK cell receptors. However,
NKp44 and NKp30 have recently been shown to exhibit both
inhibitory and activating functions. NKp44 recognizes cell sur-
face PCNA in an inhibitory manner while a soluble C-terminal
fragment of Bat3 inhibits NK cell function via NKp30 (15, 71).
However, recognition of MLL5 by NKp44- and NKp30-mediated
recognition of Bat3 sequestered to the cell surface activates NK
cell effector functions (53, 62, 63). Thus, modulation of NK cell
activity via the NCRs could depend on the DAMP molecule, the
co-ligand sequestering the DAMP, or the lack of a coligand and
the soluble nature of the DAMP. NKp44 presents a more special
case since it contains a functional ITIM-like sequence in its cyto-
plasmic tail. Due to the dual nature of NKp44 signaling, it will
be of interest to determine if recognition of the DAMP, either
PCNA or MLL5, the coligand, potentially an HSPG or HLA I,
or the motif as a whole is responsible for inhibition or activa-
tion of NK cytotoxicity. Neither NKp30 nor NKp46 has been
reported to contain an ITIM sequence. However, an immuno-
suppressive isoform of NKp30 resulting from a single-nucleotide
polymorphism in the 3′-untranslatable region has been reported
(72). Whether the divergence of NCR function depends on the
individual DAMP molecule recognized or the binding of DAMP
molecules to a specific coligand remains to be elucidated.
CONCLUDING REMARKS
Recent studies reveal a novel function for DAMP molecules, or
proteins, which are located and function intracellular, but some-
how localize to the extracellular membrane despite lacking a tra-
ditional secretory leader sequence. These proteins are released by
cells, which have become injured in the absence of infection due
to ischemia, hypoxia, transformation, chemotherapy, DNA dam-
age, or other trauma. Analogous to TLRs recognizing pathogen-
associated molecular patterns, the NCRs may represent a class of
NK cell receptors that participate in pattern recognition of DAMP
molecules, whose identities may reflect the intracellular health of a
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cell, particularly in regards to DNA damage or instability, in addi-
tion to the traditional method of HLA I presenting self peptide.
In this manner, HLA I, HSPGs, or other co-ligands may present
DAMP molecules for identification by the NCRs, which would
then regulate NK cell function. Like other NK cell receptors, the
NCRs undoubtedly recognize multiple ligands, which may be cell
surface transmembrane proteins, like the recognition of B7-H6
molecule by NKp30 (73). Knowledge of the identities of NCR lig-
ands and nature of DAMP molecules that bind to HLA I, HSPGs,
or other cell surface molecules to form complex ligands for the
NCRs will shed light on NK cell recognition of target cells under
healthy and disease conditions and offer novel therapeutic targets.
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